Capsugel targets nutra and pharma sectors with liquid lipid technology
Its Lipidex initiative will accelerate its Dosage Form Solutions (DFS) business, the company said, with “tailored solutions of low solubility drugs in their pipeline, repositioning existing drugs for better therapeutic performance or rebranding them using innovative dosage forms,” said Amit Patel, president, Capsugel DFS.
“Through Capsugel’s historical investments and our recent acquisition of Encap Drug Delivery, the LIPIDEX platform represents the industry’s most comprehensive and vertically integrated offering in the lipid, liquid and semi-solid arena. It spans polymer science and process engineering at the capsule level, as well as API handling, dosage formulation development using expert systems, clinical trial quantity supply and commercial manufacturing.”
The platform will be run out of its manufacturing sites in the US, Europe and Japan.
